Hangzhou Syno Pharmaceuticals

Syno Pharmaceuticals is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative peptide-based therapeutics. The company focuses on metabolic diseases, particularly targeting the GLP-1, GIP, and glucagon pathways for indications such as type 2 diabetes and obesity. Syno Pharmaceuticals leverages a proprietary peptide technology platform to design long-acting and multi-target agonists with improved efficacy and safety profiles. In addition to its internal pipeline, the company provides high-end pharmaceutical research and development services, including CRO services for peptide synthesis and optimization.